MRC1 and urinary bladder carcinoma: In contrast, in the MIBC cohort, there was a significant decrease in macrophages and Tregs and expression of CD206, suggesting attenuation of the immunosuppressive TME in bladder cancer upon daratumumab treatment (Fig. 3C).